Zentalis Confirms Optimal Dose for Cancer Drug; Jefferies Raises Price Target
Zentalis Pharmaceuticals (ZNTL) has finalized the optimal dose for its lead cancer drug azenosertib based on clinical trial data, prompting Jefferies to increase its price target from $2.50 to $6.00. The company is now preparing for regulatory approval and commercialization, with key data points expected in late 2026.
Tickers: $ZNTL
Topics: cancer treatment clinical trials drug development pharmaceuticals stock price target